-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team Nowadays, COVID-19 vaccination activities are being widely carried out in China and around the world.
In China, the inactivated COVID-19 vaccine developed by Sinopharm Group China Biotechnology Co.
, Ltd.
is one of the main COVID-19 vaccines people vaccinate.
Therefore, its safety and protective efficacy have also received extensive attention.
A few days ago, a safety study published in the Chinese core academic journal "Chinese Journal of Epidemiology" showed that the inactivated vaccine developed by Sinopharm Group caused a low rate of adverse reactions during large-scale emergency use, and no serious adverse reactions were found.
On April 29, the World Health Organization (WHO) Immunization Strategy Advisory Expert Group (SAGE) held a meeting to evaluate the new crown inactivated vaccine BBIBP-CorV developed by the Beijing Institute of Biological Products under the Sinopharm Group.
The materials released at the meeting showed that the effectiveness of BBIBP-CorV in the phase 3 clinical trial to prevent COVID-19 reached 78.
1%, and the effectiveness of preventing hospitalization due to COVID-19 reached 78.
7%.
In China, the inactivated COVID-19 vaccine developed by Sinopharm Group China Biotechnology Co.
, Ltd.
is one of the main COVID-19 vaccines people vaccinate.
Therefore, its safety and protective efficacy have also received extensive attention.
A few days ago, a safety study published in the Chinese core academic journal "Chinese Journal of Epidemiology" showed that the inactivated vaccine developed by Sinopharm Group caused a low rate of adverse reactions during large-scale emergency use, and no serious adverse reactions were found.
On April 29, the World Health Organization (WHO) Immunization Strategy Advisory Expert Group (SAGE) held a meeting to evaluate the new crown inactivated vaccine BBIBP-CorV developed by the Beijing Institute of Biological Products under the Sinopharm Group.
The materials released at the meeting showed that the effectiveness of BBIBP-CorV in the phase 3 clinical trial to prevent COVID-19 reached 78.
1%, and the effectiveness of preventing hospitalization due to COVID-19 reached 78.
7%.
